

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Page 1 of 2

## REQUEST FOR FILING APPLICATION

Under Rule 53(a), (b)(1) &amp; (d)(1)

(No Filing Fee or Oath/Declaration)

(Do NOT use for Provisional or PCT Applications)

Use for Design or Utility Applications

PATENT  
APPLICATION**RULE 53(d) NO DECLARATION**

Honorable Commissioner of

Atty. Dkt.

236007

PZCOM.01/US

Patents and Trademarks

Washington, DC 20231

M#

Client Ref

Date:

February 27, 1997

Sir:

1. This is a Request for filing a new Patent Application ☐ Design ☒ Utility) entitled:

2. (Complete) Title: NUCLEOTIDE SEQUENCE FOR TREATING CANCER AND INFECTION

without a filing fee or Oath/Declaration but for which is enclosed the following:

3. ☒ Abstract 1 page(s).4. 57 Pages of Specification (only spec. and claims); 5. ☐ Specification in non-English language

6. 27 Numbered claim(s); and

7. ☒ Drawings: 11 sheet(s) per set: ☒ 1 set informal; 8. ☐ formal of size: ☒ A4 ☐ 11"

9. DOMESTIC/INTERNATIONAL priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1) 08/448,590	September 28, 1995	(2)	
(3)		(4)	
(5)		(6)	

10. FOREIGN priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in Belgian

Application No.	Filing Date	Application No.	Filing Date
(1) 09201087	December 10, 1992	(2) PCT/BE 93/0080	December 10, 1993
(3)		(4)	
(5)		(6)	

11. (No.) Certified copy (copies): ☐ attached; ☐ previously filed (date) filed on in U.S. Application No. /12. ☐ Amend the specification by inserting before the first line - This is a ☐ Continuation-in-Part ☐ Divisional ☐ Continuation ☐ Substitute Application (MPEP 201.09) of:12(a) ☐ National Appln. No. / filed -- (M# )12(b) ☐ International Appln. No. PCT/ filed which designated the U.S. --13. ☒ See top of first page re continuing appln (X box only if info is there)13(a) extension to date: ☒ concurrently filed ☐ not needed ☐ previously filed14. ☒ Prior application is assigned to Z-COMPANY, S.A.

by Assignment recorded Sept mb r 28, 1995 Reel 7955 Frame 0735

15. ☐ Attached:

16. This application is made by the following named inventor(s) (Double check instructions for accuracy):

(1) Inventor	Marc		ZEICHER
	First	Middle Initial	Family Name
Residence	Brussels	Belgium	Belgium
	City	State/Foreign Country	Country of Citizenship
Post Office Address	Rue Danse, 18 B-1180 Brussels (Belgium)		
(include Zip Code)			

(2) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(3) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(4) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(5) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

17. NOTE: FOR ADDITIONAL INVENTORS, check box ☐  
and attach sheet with same information regarding additional inventors.

**Cushman Darby & Cushman  
Intellectual Property Group of  
Pillsbury Madison & Sutro LLP**

1100 New York Avenue, N.W.  
Ninth Floor, East Tower  
Washington, D.C. 20005-3918  
Tel: (202) 861-3000  
CGL/dlc

By: Atty: Carl G. Love

Sig: 

Reg. No. 18781

35843

Fax: (202) 822-0944  
Tel: (202) 861-3518

NOTE: File in duplicate with 2 post card receipts (CDC-103) & attachments

03807500-022797

# APPLICATION UNDER UNITED STATES PATENT LAWS

Invention: NUCLEOTIDE SEQUENCE FOR TREATING CANCER AND INFECTION

Inventor (s): Marc ZEICHER

Cushman Darby & Cushman  
Intellectual Property Group of  
Pillsbury Madison & Sutro, LLP  
1100 New York Avenue, N.W.  
Ninth Floor, East Tower  
Washington, D.C. 20005-3918  
Attorneys  
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☐ Regular Utility Application
- ☒ Continuation-In-Part Application
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application

## SPECIFICATION

08807500-022797